These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance. Bohlmann L; De Oliveira DMP; El-Deeb IM; Brazel EB; Harbison-Price N; Ong CY; Rivera-Hernandez T; Ferguson SA; Cork AJ; Phan MD; Soderholm AT; Davies MR; Nimmo GR; Dougan G; Schembri MA; Cook GM; McEwan AG; von Itzstein M; McDevitt CA; Walker MJ mBio; 2018 Dec; 9(6):. PubMed ID: 30538186 [TBL] [Abstract][Full Text] [Related]
3. Disruption of Metallostasis in the Anaerobic Human Pathogen Van Zuylen EM; Ferguson SA; Hughes A; Rennison D; Brimble MA; Cook GM ACS Infect Dis; 2021 Aug; 7(8):2285-2298. PubMed ID: 34259502 [TBL] [Abstract][Full Text] [Related]
4. Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria. De Oliveira DMP; Keller B; Hayes AJ; Ong CY; Harbison-Price N; El-Deeb IM; Li G; Keller N; Bohlmann L; Brouwer S; Turner AG; Cork AJ; Jones TR; Paterson DL; McEwan AG; Davies MR; McDevitt CA; Itzstein MV; Walker MJ Antibiotics (Basel); 2022 Mar; 11(4):. PubMed ID: 35453201 [TBL] [Abstract][Full Text] [Related]
5. Repurposing the Ionophore, PBT2, for Treatment of Multidrug-Resistant Neisseria gonorrhoeae Infections. Jen FE; Edwards JL; El-Deeb IM; Walker MJ; von Itzstein M; Jennings MP Antimicrob Agents Chemother; 2022 Sep; 66(9):e0231821. PubMed ID: 35980187 [TBL] [Abstract][Full Text] [Related]
6. Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model. Brazel EB; Tan A; Neville SL; Iverson AR; Udagedara SR; Cunningham BA; Sikanyika M; De Oliveira DMP; Keller B; Bohlmann L; El-Deeb IM; Ganio K; Eijkelkamp BA; McEwan AG; von Itzstein M; Maher MJ; Walker MJ; Rosch JW; McDevitt CA Cell Rep; 2022 Jan; 38(2):110202. PubMed ID: 35021083 [TBL] [Abstract][Full Text] [Related]
7. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. Faux NG; Ritchie CW; Gunn A; Rembach A; Tsatsanis A; Bedo J; Harrison J; Lannfelt L; Blennow K; Zetterberg H; Ingelsson M; Masters CL; Tanzi RE; Cummings JL; Herd CM; Bush AI J Alzheimers Dis; 2010; 20(2):509-16. PubMed ID: 20164561 [TBL] [Abstract][Full Text] [Related]
8. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. Crouch PJ; Savva MS; Hung LW; Donnelly PS; Mot AI; Parker SJ; Greenough MA; Volitakis I; Adlard PA; Cherny RA; Masters CL; Bush AI; Barnham KJ; White AR J Neurochem; 2011 Oct; 119(1):220-30. PubMed ID: 21797865 [TBL] [Abstract][Full Text] [Related]
9. A drug candidate for Alzheimer's and Huntington's disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides. Jen FE; El-Deeb IM; Zalucki YM; Edwards JL; Walker MJ; von Itzstein M; Jennings MP J Antimicrob Chemother; 2021 Oct; 76(11):2850-2853. PubMed ID: 34450628 [TBL] [Abstract][Full Text] [Related]
10. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. Adlard PA; Bica L; White AR; Nurjono M; Filiz G; Crouch PJ; Donnelly PS; Cappai R; Finkelstein DI; Bush AI PLoS One; 2011 Mar; 6(3):e17669. PubMed ID: 21412423 [TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of the antibiotic clioquinol. Ding WQ; Liu B; Vaught JL; Yamauchi H; Lind SE Cancer Res; 2005 Apr; 65(8):3389-95. PubMed ID: 15833873 [TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW; Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400 [TBL] [Abstract][Full Text] [Related]
13. Association between antimicrobial use and antimicrobial resistance of Streptococcus uberis causing clinical mastitis. Martins L; Gonçalves JL; Leite RF; Tomazi T; Rall VLM; Santos MV J Dairy Sci; 2021 Nov; 104(11):12030-12041. PubMed ID: 34389143 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance in Staphylococcus aureus, Streptococcus uberis and Streptococcus dysgalactiae from dairy cows with mastitis. McDougall S; Hussein H; Petrovski K N Z Vet J; 2014 Mar; 62(2):68-76. PubMed ID: 24215609 [TBL] [Abstract][Full Text] [Related]
15. Repurposing Ionophores as novel antimicrobial agents for the treatment of bovine mastitis caused by Gram-positive pathogens. Hickey EE; Wong HS; Khazandi M; Ogunniyi AD; Petrovski KR; Garg S; Page SW; O'Handley R; Trott DJ J Vet Pharmacol Ther; 2018 Oct; 41(5):746-754. PubMed ID: 29971788 [TBL] [Abstract][Full Text] [Related]
17. Susceptibility to antimicrobials of mastitis-causing Staphylococcus aureus, Streptococcus uberis and Str. dysgalactiae from New Zealand and the USA as assessed by the disk diffusion test. Petrovski KR; Grinberg A; Williamson NB; Abdalla ME; Lopez-Villalobos N; Parkinson TJ; Tucker IG; Rapnicki P Aust Vet J; 2015 Jul; 93(7):227-33. PubMed ID: 26113347 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Huntington Study Group Reach2HD Investigators Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848 [TBL] [Abstract][Full Text] [Related]
19. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Sampson EL; Jenagaratnam L; McShane R Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468 [TBL] [Abstract][Full Text] [Related]
20. Ionophore resistance of ruminal bacteria and its potential impact on human health. Russell JB; Houlihan AJ FEMS Microbiol Rev; 2003 Apr; 27(1):65-74. PubMed ID: 12697342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]